Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Recruiting 8Unknown 7Terminated 4Not yet recruiting 4Completed 4Active not recruiting 3Approved for marketing 2Withdrawn 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 50Stomach Neoplasms 7Neoplasm Metastasis 5Colorectal Neoplasms 4Uterine Cervical Neoplasms 3HER2-positive Breast Cancer 3Esophageal Neoplasms 3Uterine Neoplasms 2Solid Tumors 2Lung Neoplasms 2Inflammatory Breast Neoplasms 2Gallbladder Neoplasms 2Endometrial Neoplasms 2Cholangiocarcinoma 2Carcinoma, Non-Small-Cell Lung 2Breast Diseases 2Brain Neoplasms 2Biliary Tract Neoplasms 2Anatomic Stage II Breast Cancer AJCC v8 2Adenocarcinoma Of Esophagus 2Urologic Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Solid Cancer 1Rectal Neoplasms 1Prostatic Neoplasms 1Patient Compliance 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1

Interventions

pertuzumab 3Trastuzumab 3Paclitaxel 2Docetaxel 2tucatinib 1trastuzumab deruxtecan 1pegfilgrastim 1atezolizumab 1Carboplatin 1Ado-Trastuzumab Emtansine 1ARX788 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × HER2-positive Breast Cancer × Trastuzumab × Clear all
NCT03125928 2026-05-22

Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

Fox Chase Cancer Center

Phase 2 Active not recruiting
16 enrolled
Breast

HER2-positive Breast Cancer

NCT03571633 2025-11-26

BREASTIMMU02

Centre Leon Berard

Phase 2 Active not recruiting
90 enrolled
Breast

HER2-positive Breast Cancer

NCT05426486 2024-10-30

A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

Shengjing Hospital

Phase 2/3 Active not recruiting
136 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡